Dr. Burney MD/MBBS, CIT, has been conducting and teaching research to medical students and residents for over a decade. Soon after graduating from medical school, he decided to pursue a career in research. He practiced as a primary care physician for a few years before joining the University of California Davis (UC Davis) and completed 6 years of postdoc then continued as a visiting scholar at UC Davis and joined California State University Sacramento (CSUS) as a Research Fellow. Meanwhile, he has also served at the UC Davis Medical Center, Sutter Health Davis Medical Center, CA, and Napa State Hospital, CA. Besides his medical degree, he is also certified in Information Technology and incorporates modern technology with research to find cures for undiscovered modalities.

During his research career, he has gained immense hands-on experience in clinical and basic science research. He has about 100 publications and several ongoing projects in multiple disciplines. He has been working on over 40 FDA regulated clinical trials on vitiligo, eczema, hidradenitis suppurativa, and achalasia. He also serves as a reviewer for several medical journals and loves to present papers at international conferences. When free, he likes to spend time with family, traveling, and cooking.

Basic Science Research Procedures

• Western blots
• Flow cytometry
• Human and microbial cell culture
• Primary human cell isolation
• DNA and RNA extraction
• ELISA
• Lipid analysis assays
• Cell proliferation assays
• Cytotoxicity assays
• Tissue staining and processing
• UVA experiments
• Blood processing
• Human clinical sample collection, and processing.

Publications

Peer Reviewed Journal Articles/Abstracts

• Burney, W., R, Isseroff., & Sivamani, R.K. 878 Influence of bovine milk oligosaccharides on sebocyte lipid contents and inflammatory mediators. Journal of Investigative Dermatology (JID). 2017, May; 137(1): S151. Pub Status: Published.
• Burney, W.A., Bosanac, S.S., Nguyen, C., Isseroff, R.R., & Sivamani, R.K. Short-term exposure of human sebocytes to 13-cis retinoic acid induces acnegenic changes. British Journal of Dermatology. 2018, Nov; 179(5): 1201-1202. Cited in PubMed; PMID: 29934942. Pub Status: Published.
• Burney, W.A., Fakih, H.A., Fakih, M., Iftikhar, R., & Urooj, A. Knowledge of doctors working in Karachi about Vitamin D deficiency. Pakistan Journal of Medical Sciences. 2011, Jun; 27(2): 357-360. Pub Status: Published.
• Burney. W., Saric. S., Davis. S., Rosen. D., & Sivamani. R.K. 1150 UVA light and oxidative stress. Journal of Investigative Dermatology. 2018, May; 138(5): S195. Pub Status: Published.
• Dhaliwal, S., Rybak, I., Ellis, S.R., Notay, M.,Trivedi, M., Burney, W., Vaughn, A.R., Nguyen, M., Reiter, P., Bosanac, S.,Yan, H., Foolad, N., & Sivamani, R.K. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. British Journal of Dermatology. 2019, Feb; 2(180): 289-296. Cited in PubMed; PMID: 29947134. Pub Status: Published.
• Dhaliwal, S., Rybak, I., Pourang, A., Burney, W., Hass, K., Sandhu, S., Crawford, R., Sivamani, R.K. Randomized double-blind vehicle-controlled study of the effects of topical acetyl zingerone on photoaging. J Cosmet Dermatol. 2021, Jan;20(1):166-173. Cited in PubMed; PMID: 32369655. Pub Status: Published.
• Rybak, I., Carrington, A.E., Dhaliwal, S., Hasan, A., WU, H., Burney, W., Maloh, J., & Sivamani, R.K. Prospective Randomized Controlled Trial on the Effects of Almonds on Facial Wrinkles and Pigmentation. Nutrients. 2021 Feb 27;13(3):785. Cited in PubMed; PMID: 33673587. Pub Status: Published.
• Ellis, S.R., Nguyen, M., Vaughn, A,R., Notay, M., Burney, W.A., Sandhu, S., & Sivamani, R.K. The Skin and Gut Microbiome and Its Role in Common Dermatologic Conditions. Microorganisms. 2019, Nov; 7(11): online. Cited in PubMed; PMID: 31717915. Pub Status: Published.
• Foolad, N., Burney, W., Shafizadeh, T., Watkins, S., & Sivamani, R.K. 293 The influence of tretinoin and isotretinoin on the sebaceous gland lipidome and lipid mediators. Journal of Investigative Dermatology (JID). 2016, May; 136(5): S51. Pub Status: Published.
• Foolad, N., Saric, S., Burney, W., & Sivamani, R.K. The Role of Nutrition in Dermatology. Austin Journal of Dermatology. 2017, Jun; 4(1): 1072. Pub Status: Published.
• Foolad, N., Vaughn, A.R., Rybak, I., Burney, W.A., Chodur, G.M., Newman, J.W., Steinberg, F.M., & Sivamani, R.K. Prospective randomized controlled pilot study on the effects of almond consumption on skin lipids and wrinkles. Phytother Res. 2019, Oct; 33(12): 3212-3217. Cited in PubMed; PMID: 31576607. Pub Status: Published.
• Fuentes, J., Foolad, N., Burney, W., Shafizadeh, T., Singh, S., Watkins, S., Crawford, R.W., & Sivamani, R.K. 694 Retinoid induced changes in the fatty acid profile of sebum and its effect on bacterial growth. Journal of Investigative Dermatology (JID). 2016, May; 136(5): S123. Pub Status: Published.
• Haas, K., Notay, M., Rodriguez, W., Rolston, M., Clark, A., Burney, W., Newman, J.W., Pedersen, T., Crawford, R., Dandekar, S., & Sivamani, R.K. 383 Doxycycline effects on the gut and skin microbiomes and lipidome in acne. Journal of Investigative Dermatology. 2018, May; 138(5): S65. Pub Status: Published.
• Iftikhar, R., & Burney, W.A. An experience with a single layer uterine closure and JOEL-COHEN abdominal approach for caesarean section. Journal of Surgery Pakistan (International). 2010, Jun; 2(15): 103-106. Pub Status: Published.
• Iftikhar, R., & Burney, W.A. Role of Misoprostol in inducing abortion in previous caesarean section. Journal of Surgery Pakistan (International). 2009, Sep; 3(14): 120-123. Pub Status: Published.
• Iftikhar, R., & Burney, W.A. Physicians knowledge regarding dengue haemorrhagic fever. ISRA MEDICAL JOURNAL. 2012, Jun; 4(2): 86-89. Pub Status: Published.
• Mubarik, A., Burney, W., Khan, S.A., Qasim, M., Basit, M., & Hassan, S.M. Prevalence of Comorbididites in Obstructive Sleep Apnea Population Waiting for Bariatric Surgery. Journal of General and Emergency Medicine. 2017, Sep; 2(6): 1-5. Pub Status: Published.
• Mubarik, A., Khan, S.A., Burney, W., Qasim, M., & Basit, M. The Prevalence and Predictors of Obstructive Sleep Apnea in Bariatric Surgery Candidates. Clinical Pulmonary Medicine. 2016, Sep; 23(5): 210-215. Pub Status: Published.
• Nguyen, M., Ferge, K.K, Vaughn, A.R., Burney, W., Teng. L.H., Pan, A., Nguyen, V., & Sivamani, R.K. Probiotic Supplementation and Food Intake and Knowledge Among Patients and Consumers. Probiotics Antimicrob Proteins. 2020, Sept;12(3):824-833. Cited in PubMed; PMID: 31713116. Pub Status: Published.
• Notay, M., Bosanac, S.S., Vaughn, A.R., Dhaliwal, S., Trivedi, M., Reiter, P.N., Rybak, I., Li, C.C., Weiss, L.B., Ambrogio, L., Burney, W.A., & Sivamani, R.K. The use of topical Nitrosomonas eutropha for cosmetic improvement of facial wrinkles. Journal of Cosmetic Dermatology. 2020, Mar; 19(3): 689-693. Cited in PubMed; PMID: 31257694. Pub Status: Published.
• Ornelas, J., Foolad, N., Shi, V., Burney, W., & Sivamani, R.K. Effect of Microneedle Pretreatment on Topical Anesthesia: A Randomized Clinical Trial. JAMA Dermatology. 2016, Apr; 152(4): 476-477. Cited in PubMed; PMID: 26762206. Pub Status: Published.
• Shi.V.Y., Foolad.N., Ornelas.J., Burney.W., Maarouf.M., Hassoun.L., Monico.G., Takeda.N., Bosanac.S., Eichenfield.L.F., & Sivamani.R.K. The Comparative Effects of Various Moisturizers on Epidermal Barrier Function Recovery After Bathing in Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 2018, Jul; 2(4): 219-223. Pub Status: Published.
• Siddiqui, M.S., Fakih, H.A., Burney, W.A., Iftikhar, R., & Khan, N. Environmental and Host-Related Factors Predisposing to Tuberculosis in Karachi: A Cross-Sectional Study. Journal of Pioneering Medical Sciences. 2011, Jun; 1(1): 13-18. Pub Status: Published.
• Singh, S., Burney, W., Fuentes, J., Crawford, R.W., & Sivamani, R. 651 Microbiome-free fatty acid cross-talk in the human pilosebaceous gland. Journal of Investigative Dermatology. 2017, May; 137(1): S112. Pub Status: Published.
• Tohid, H., Shenefelt, P.D., Burney, W.A., & Aqeel, N. Psychodermatology: An Association of Primary Psychiatric Disorders With Skin. Rev Colomb Psiquiatr. 2019, Jan; 48(1): 50-57. Cited in PubMed; PMID: 30651173. Pub Status: Published.
• Vaughn, A.R., Haas, K.N., Burney, W., Andersen, E., Clark, A.K., Crawford, R., & Sivamani, R.K. Potential Role of Curcumin Against Biofilm-Producing Organisms on the Skin: A Review. Phytotherapy Research. 2017, Dec; 31(12): 1807-1816. Cited in PubMed; PMID: 28884496. Pub Status: Published.
• Vaughn, A.R., Pourang A,. Clark, A.K., Burney, W., & Sivamani, R.K. Dietary supplementation with turmeric polyherbal formulation decreases facial redness: a randomized double-blind controlled pilot study. Journal of Integrative Medicine. 2019, Jan; 17(1): 20-23. Cited in PubMed; PMID: 30527287. Pub Status: Published.

Poster Presentations

• Agrawal, K., Burney, W., Sharma, S., Dallas, D., German, J.B., Newman, J.W., & Sivamani, R.. (2015, June). Impact of Milk Peptides on Sebocyte Lipid Mediators [Poster presented]. Metabolomics 2015/San Francisco, CA, USA.
• Burney, W., R, Isseroff., & Sivamani, R.K. (2017, April). Influence of bovine milk oligosaccharides on sebocyte lipid contents and inflammatory mediators [Poster presented]. Society of Investigative Dermatology, 76th annual meeting 2017/Portland, OR, USA.
• Chakkalakal, M., Nadora, D., Burney, W., Chambers, C.J., & Sivamani, R.K. (2021, October). Prospective Randomized DoubleBlind Placebo- Controlled Study of Oral Pomegranate Extract on Skin and Gut Health. [Poster presented]. Integrative Dermatology Symposium/Sacramento, CA, USA.
• Chakkalakal, M., Nadora, D., Burney, W., Chambers, C.J., & Sivamani, R.K. (2022, September). Prospective Randomized Double-Blind Placebo-Controlled Study of Oral Pomegranate Extract on Skin and Gut Health. [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Chakkalakal, M., Pan, A., Nadora, D., Gahoonia, N., Dumont, A., Burney, W., Chambers, C.J., Sivamani, R.K. (2022, September). P rospective Randomized Double-Blind Placebo-Controlled Study of Oral Pomegranate Extract on Skin Health, Skin Microbiome, and Influence on the Gut-Skin Axis. [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Chakkalakal, M., Pan, A., Nadora, D., Gahoonia, N., Thacker, S., Shakhbazova, A., Burney, W., Chambers, C.J., & Sivamani, R.K. (2022, September). Randomized Double-Blind Placebo-Controlled Supplementation With Standardized Terminalia Chebula Fruit Reduces Facial Sebum Excretion, Erythema, and Wrinkle Severity. [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Clark, A.K., Burney, W., & Sivamani, R.K. (2015, March). Characterization of siRNA Knockdown Of Raptor and Rictor in Human Sebocytes [Poster presented]. UC Davis School of Medicine Poster Day 2015/Sacramento, CA, USA.
• Foolad, N., Burney, W., Shafizadeh, T., Watkins, S., & Sivamani, R. (2016, May). The influence of retinoids on the sebocyte and sebum lipidome and lipid mediators [Poster presented]. Department of Dermatology Symposium 2016; Sacramento, CA/Sacramento, CA, USA.
• Foolad, N., Burney, W., Shafizadeh, T., Watkins, S., & Sivamani, R. (2016, September). The influence of retinoids on the sebocyte and sebum lipidome and lipid mediators [Poster presented]. Department of Dermatology Symposium/Sacramento, CA, USA.
• Foolad, N., Shafizadeh, T., Watkins, S., Nguyen, U., Ornelas, J., Burney, W., & Sivamani, R.K. (2015, September). The Effect of Topical and Systemic Retinoids on the Sebum Lipid Profile in Acne [Poster presented]. European Society for Dermatological Investigation annual meeting/Rotterdam, NLD.
• Maloh, J., Bensen, K., Chakkalakal, M., Burney, W., Kumar, S., & Sivamani, R.K. (2021, October). Prospective, Randomized, Double-Blind Placebo-Controlled Study of Oral Spore- Based Probiotics on Non-Cystic Acne Vulgaris. [Poster presented]. Integrative Dermatology Symposium/Scaramento, CA, USA.
• Maloh, J., Bensen, K., Chakkalakal, M., Burney, W., Kumar, S., & Sivamani, R.K. (2022, September). Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Oral Spore- Based Probiotics on Non- Cystic Acne Vulgaris [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Natarelli, N., Gahoonia, N., Subramanyam, C., Burney, W., Sivamani, R.K., & Maloh, J . (2022, September). The Effect of Heating Devices on Mood and Anxiety [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Ornelas J., Burney, W., Dallas, D., Sharma, S., Agrawal, K., Newman, J., German, B.J., & Sivamani, R.K. (2015, March). Effect Of Milk Peptides and Azadirachta Indica on the Eiconsanoid Pathway in Sebocytes [Poster presented]. UC Davis School of Medicine Medical Student Research Conference/Sacramento, CA, USA.
• Ornelas J., Burney, W., Dallas, D., Sharma, S., Agrawal, K., Newman, J., German, B.J., & Sivamani, R.K.. (2015, April). Effect of Milk Peptides and Azadirachta Indica on the Eiconsanoid Pathway in Sebocytes [Poster presented]. Translational Science Meeting/Washington, DC, USA.
• Pan, A., Burney, W., Clark, A.K., Dhaliwal, S., Isseroff, R.R., & Sivamani, R.K. (2022, September). Bovine Milk Oligosaccharides Increase Sebocyte Lipogenesis and Inflammation and Activate the mTOR Pathway [Poster presented]. Integrative Dermatology Symposium./Tucson, AZ, USA.
• Pourang, A., Dhaliwal, S., Wu, H., Hasan, A., Burney, W., Miles, M., Rybak, I., Veerula, V., & Sivamani, R.K . (2020, October). The Effects of Mineral Clay Masks on Skin Biophysical Properties: A Randomized Clinical Trial [Poster presented]. Integrative Dermatology Symposium/Sacramento, CA, USA.
• Rizzo, J., Nong, Y., Shakhbazova, A., Pan, A., Burney, W., Subramanyam, C., McCoy, T., Maloh, J., & Sivamani, R.K. (2022, September). Prospective, Randomized, Open-Label Assessment of Almond Oil vs Retinol on Facial Wrinkles and Biophysical Features. [Poster presented]. Integrative Dermatology Symposium/Tucson, AZ, USA.
• Singh, S., Burney, W., Fuentes, J., Crawford, R.W., & Sivamani, R.K. (2017, April). Microbiome-free fatty acid cross-talk in the human pilosebaceous gland [Poster presented]. Society of Investigative Dermatology, 76th annual meeting 2017/Portland, OR, USA.
• Wu, H., Gabriel, T.A., Burney, W.A., Chambers, C.J., & Sivamani, R.K . (2020, October). Split- body comparison of hydroquinine and hexylresorinol for skin pigment appearance. [Poster presented]. Integrative Dermatology Symposium/Sacramento, CA, USA.

FDA Regulated Clinical Trials:

• A Phase 3b Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating Safety and Efficacy of X Compared to Placebo in Adult Subjects with Moderate to Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement (PPPsO). Sponsor: Abbvie, Protocol Number: M15-994
• A Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of X in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis. Sponsor: Abbvie, Protocol Number: M19-977
• A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of X in Subjects With Moderate to Severe Chronic Plaque Psoriasis Who Have Completed Participation in Study M19-977. Sponsor: Abbvie, Protocol Number: M19-973.
• A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of X Cream 0.15% Administered QD in Subjects with Atopic Dermatitis. Sponsor: Arcutis, Protocol Number: ARQ-151-311.
• A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of X Cream 0.05% Administered QD in Subjects with Atopic Dermatitis. Sponsor: Arcutis, Protocol Number: ARQ-151-315.
• A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of X Cream 0.15% and X Cream 0.05% in Subjects with Atopic Dermatitis. Sponsor: Arcutis, Protocol Number: ARQ-151-313.
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of X in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease modifying Anti-rheumatic Drugs. Sponsor: BMS, Protocol Number: IM011-054.
• A multicenter, randomized, double-blind, placebo-controlled study evaluating the effect of X on quality of life in participants with plaque psoriasis in a community setting (ARTISTYK). Sponsor: BMS, Protocol Number: IM011-237.
• An open-label, single-arm study to assess the safety and efficacy of X in adolescent patients with moderate-to-severe atopic dermatitis. Sponsor: Dermira, Protocol Number: J2T-DM-KGAE (DRM06-AD17).
• A long-term study to assess the safety and efficacy of X in patients with moderate-to-severe atopic dermatitis. Sponsor: Dermira, Protocol Number: J2T-DM-KGAA (DRM06-AD07).
• A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of X in Subjects with Prurigo Nodularis. Sponsor: Galderma, Protocol Number: RD.SPR.202685.
• A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of X in Subjects with Prurigo Nodularis. Sponsor: Galderma, Protocol Number: RD.SPR.202699.
• A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of X for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsor: Janssen, Protocol Number: 77242113PSO2001.
• A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of X for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsor: Janssen, Protocol Number: 77242113PSO2002.
• An observational cohort study of atopic dermatitis patients prescribed X. Sponsor: LEO Pharma,Protocol Number: NIS-TRALO-2213.
• A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of X Compared to Placebo in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis. Sponsor: Eli Lilly, Protocol Number: J2T-MC-KGBI.
• Patient and clinician Reported Outcomes for X effectiveness and safety in Actinic Keratosis (PROAK). Sponsor: Avant Health, Protocol Number: M-14789-43.
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of X in Participants With Hidradenitis Suppurativa. Sponsor: Incyte, Protocol Number: INCB54707-204.
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of X Followed by an Extension Period in Participants With Vitiligo. Sponsor: Incyte, Protocol Number: INCB54707-205.
• A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of X Cream Followed by an Extension Period in Participants With Vitiligo. Sponsor: Incyte, Protocol Number: INCB18424-307.
• A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of X Cream in Participants With Vitiligo. Sponsor: Incyte, Protocol Number: INCB18424-308.
• A Phase 3 Efficacy and Safety Study of X for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults. Sponsor: Dermavant, Protocol Number: DMVT-505-3101.
• An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of X Cream 1% in Subjects with Atopic Dermatitis. Sponsor: Dermavant, Protocol Number: DMVT-505-3103.
• A Phase 2 Study to Evaluate the Efficacy and Safety of X as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis. Sponsor: RAPT, Protocol Number: RPT193-02.
• A two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral X as adjunct therapy to a topical corticosteroid for moderate to severe pruritus in adult subjects with atopic dermatitis. Sponsor: CARA, Protocol Number: CR845-310501.
• A randomized, double-blinded, placebo-controlled, multicenter Phase 2 study evaluating the efficacy and safety of X in participants with moderate-to-severe plaque psoriasis. Sponsor: Highlightll Pharmaceutical, Protocol Number: TLL018-205.
• A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of X in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis. Sponsor: BMS, Protocol Number: IM011-1130
• A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis. Sponsor: BMS, Protocol Number: IM011-1128
• A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of X in Participants with Active Psoriatic Arthritis (PsA) who are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or had Previously Received TNFα Inhibitor Treatment. Sponsor: BMS, Protocol Number: IM011-055
• A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of X in Participants 6 Months to <18 Years of Age with Moderate-to-Severe Atopic Dermatitis. Sponsor: Eli Lilly, Protocol Number: J2T-MC-KGBJ.
• A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of X in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. Sponsor: Abbvie, Protocol Number: M23-698
• A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of X on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET – VOYAGER). Sponsor: Amgen, Protocol Number: 20210158
• Rocatinlimab (AMG 451) 20210146: A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of X in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND). Sponsor: Amgen, Protocol Number: 20210146
• Amgen, Inc. / “A Phase 3, Randomized, 52 week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of X in Adolescent Subjects with Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)”. Sponsor: Amgen, Protocol Number: 20210145
• A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of X in Subjects with Active Psoriatic Arthritis. Sponsor: Acelyrin, Protocol Number: 22104
• A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of X in adult and adolescent subjects with severe alopecia areata. Sponsor Abbvie, Protocol Number: M23-716
• Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy
  and safety of X in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1. Sponsor: Boehringer Ingelheim International GmbH, Protocol Number: 1368-0098
• AbbVie Inc. / “OptIMMize-2: X in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)” Sponsor AbbVie, Protocol Number: M19-973
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and X Active Comparatorcontrolled Study to Evaluate the Efficacy and Safety of X for the Treatment of Participants With Moderate to Severe Plaque Psoriasis.
  Sponsor: Janssen, Protocol Number: 77242113PSO3002.
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the
  Efficacy and Safety of X for the Treatment of Participants with Moderate to Severe Plaque
  Psoriasis with Randomized Withdrawal and Retreatment.
  Sponsor: Janssen, Protocol Number: 77242113PSO2002

Completed Projects in Process of Publication

• Role of mTOR inhibitors in Acne Pathogenesis
• Influence of Milk Peptides and alpha and beta casein on Sebocyte lipid contents and inflammatory mediators
• Bovine milk oligosaccharides modulate inflammatory mediators and sebocyte lipid contents
• Influence of ultraviolet rays (UVA) and oxidative stress on human skin and thymine dimer production
• Effect of curcumin on biofilm production
• The effect of acne and doxycycline on the gut microbiome and lipidome
• Gut skin lipidome
• Differential effects of short and long chain fatty acids on growth and biofilm of bacterial skin commensals and pathogens present in acne
• The effects of Gotu Kola and pioglitazone on sebocyte inflammation and lipid production
• The Use of Microneedle with Topical Botulinum Toxin for treatment of palmer hyperhidrosis
• A randomized double-blind split-body placebo-controlled pilot study of topical Centella asiatica for the treatment of existing white stretch marks
• The effect of synthetic Acetyl Hexapeptide-8 (Argireline) on sebaceous function
• Chronic Anxiety Disorder leading to Achalasia